Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

261
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
261
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

722
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
722
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.6K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endurance exercise remodels pulmonary vein sleeve myocytes and promotes a proarrhythmic atrial substrate.

European heart journal·2026
Same author

Beta-cardiotoxin, a funny current inhibitor, and its effect on ion channels involved in heart rate regulation and on calcium transient profile in mouse sinoatrial node cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

AMPK-mediated HCN4 channel phosphorylation contributes to age-related intrinsic bradycardia.

The Journal of general physiology·2026
Same author

L-Type Ca<sub>v</sub>1.3 and HCN Channels Mediate Heart Rate Acceleration by Catecholamines.

Circulation research·2025
Same author

Extracellular activation of HCN4 by a subtype-specific nanobody.

Nature communications·2025
Same author

Bisphenol analogue exposure at low concentrations modifies heart-brain functions and transcriptomics in zebrafish larvae.

Journal of hazardous materials·2025
Same journal

Navigating the Computational Landscape for Drug Repurposing.

Annual review of pharmacology and toxicology·2026
Same journal

Microplastics and Atherosclerosis: Mechanisms.

Annual review of pharmacology and toxicology·2026
Same journal

Treating Pregnant and Lactating Women: Insights from Clinical Pharmacology.

Annual review of pharmacology and toxicology·2026
Same journal

<i>Caenorhabditis elegans</i> as a Model System for Environmental Mitotoxicants.

Annual review of pharmacology and toxicology·2025
Same journal

Introduction to the Theme "New Approaches, Technology, and Techniques That Advance Pharmacology and Toxicology".

Annual review of pharmacology and toxicology·2025
Same journal

A Mechanistic Framework for Repurposing FDA-Approved Drugs to Combat Antimicrobial Resistance: The Case of <i>Staphylococcus aureus</i>.

Annual review of pharmacology and toxicology·2025
See all related articles

Related Experiment Video

Updated: Dec 6, 2025

Methods for the Isolation, Culture, and Functional Characterization of Sinoatrial Node Myocytes from Adult Mice
09:32

Methods for the Isolation, Culture, and Functional Characterization of Sinoatrial Node Myocytes from Adult Mice

Published on: October 23, 2016

14.0K

Pharmacologic Approach to Sinoatrial Node Dysfunction.

Pietro Mesirca1,2, Vadim V Fedorov3,4, Thomas J Hund3,5

  • 1Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 34096 Montpellier, France;

Annual Review of Pharmacology and Toxicology
|October 5, 2020
PubMed
Summary
This summary is machine-generated.

Sino-atrial node dysfunction (SND) impairs the heart's natural pacemaker. This review covers SND causes, increasing incidence, and potential new drug therapies to manage this condition.

Keywords:
Cav1.3G protein–activated K+ channelsSANankyrin-Bsinoatrial node dysfunctiontertiapin-Q

More Related Videos

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

3.4K
High-resolution Optical Mapping of the Mouse Sino-atrial Node
11:07

High-resolution Optical Mapping of the Mouse Sino-atrial Node

Published on: December 2, 2016

16.4K

Related Experiment Videos

Last Updated: Dec 6, 2025

Methods for the Isolation, Culture, and Functional Characterization of Sinoatrial Node Myocytes from Adult Mice
09:32

Methods for the Isolation, Culture, and Functional Characterization of Sinoatrial Node Myocytes from Adult Mice

Published on: October 23, 2016

14.0K
Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

3.4K
High-resolution Optical Mapping of the Mouse Sino-atrial Node
11:07

High-resolution Optical Mapping of the Mouse Sino-atrial Node

Published on: December 2, 2016

16.4K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pathophysiology

Background:

  • Sino-atrial node dysfunction (SND) disrupts normal heartbeat generation.
  • SND is often linked to aging and fibrosis but also has genetic and systemic causes.
  • The incidence of SND is projected to rise, increasing demand for pacemakers.

Purpose of the Study:

  • To review current knowledge on sino-atrial node dysfunction mechanisms.
  • To discuss the potential for novel pharmacological treatments for SND.
  • To highlight advancements in understanding sino-atrial node physiology.

Main Methods:

  • Literature review of sino-atrial node physiology and dysfunction.
  • Analysis of pathophysiological mechanisms underlying SND.
  • Exploration of emerging therapeutic strategies for SND.

Main Results:

  • SND encompasses age-related, genetic, and secondary forms.
  • Understanding of SND mechanisms has significantly improved.
  • Pharmacological therapies for SND are being explored.

Conclusions:

  • SND is a growing clinical concern with diverse etiologies.
  • Further research into SND mechanisms may lead to new treatments.
  • Pharmacological interventions could complement or reduce reliance on pacemakers.